Original reporting and analysis on the stories shaping biotech.
Astellas just dropped $335 million upfront on a cancer drug that stays completely dormant until it reaches the tumor; then it wakes up and attacks. The early data on VIR-5500 is turning heads, and the deal's timing tells you everything about Astellas' post-XTANDI anxiety.
For decades, patients with one of the rarest metabolic diseases on earth had exactly one treatment option: an impossibly strict diet. The FDA just approved the first drug that attacks the actual problem, and the ripple effects could reshape how ultra-rare diseases get treated.
Friedreich's ataxia affects 5,000 Americans with zero approved disease-modifying treatments. Larimar Therapeutics just earned FDA Breakthrough Therapy Designation for a drug that restored frataxin to carrier levels and improved all four clinical measures, and they're filing for approval in June.
Iovance's TIL therapy just posted a 50% response rate in sarcoma, a cancer where the current standard barely helps 5% of patients. Six patients could reshape how we think about immunotherapy in "cold" tumors.
The FDA just proposed a framework that could let gene therapies win approval based on a single patient's data, no randomized trials required. It might be the biggest change to drug approvals since 1992, and it could unlock treatments for hundreds of diseases pharma has long ignored.
The FDA just cleared a smartphone app as a prescription treatment for preventing migraines, and the clinical trial data is surprisingly strong. Click Therapeutics' CT-132 could reshape how we think about treating neurological conditions, if it can survive the graveyard that swallowed its competitors.
Novo Nordisk unveiled 19.7% weight loss data for its triple agonist UBT251, conveniently one day after CagriSema flopped against Lilly's Zepbound. The numbers are real, but the competitive gap might be even realer.
Protara's TARA-002 posted an impressive 68% complete response rate in tough-to-treat bladder cancer patients at six months, then watched it crater to 33% at twelve months. It's a cautionary tale about the gap between flashy interim data and real-world durability.
GSK just locked in a $250 million, five-year deal with Bora Pharmaceuticals to spread production of 335 products across three North American facilities. It's not the biggest pharma deal of the year, but it might be the most revealing about where the industry is headed.
The FDA just told gene therapy startups they can stop burning tens of millions on factory buildouts before proving their therapies work. It's a seismic shift in how these companies get to clinical proof-of-concept, and it couldn't come at a more complicated time for biotech fundraising.
Gilead is paying $7.8 billion for a CAR-T therapy the FDA hasn't approved yet, a 68% premium that looks less like confidence and more like a rescue mission. With its existing cell therapy business shrinking, the company is betting everything on a drug that oncologists already prefer over the competition.
Moderna handed Recordati the commercial rights to a potentially first-in-class rare disease therapy for just $50 million upfront. Leerink analysts called it a "garage sale," and the math backs them up.
Eli Lilly just dropped $85 million upfront, with $1.84 billion more on the table, to partner with Repertoire Immune Medicines on a radical idea: retraining the immune system instead of suppressing it. If it works, autoimmune patients might finally escape lifelong drug regimens.
Gossamer Bio's lead drug missed the main goal of its Phase 3 trial in a deadly lung disease, then the company announced it's heading to the FDA anyway. It's either the boldest regulatory gamble of the year or a case study in denial.
Novo Nordisk built an entire clinical trial to prove CagriSema could match Eli Lilly's Zepbound. It couldn't, and the stock lost 15% before lunch. Now the company is scrambling with price cuts, higher doses, and a comeback plan that might arrive too late.
Big pharma is spending record billions on rare disease, but only on drugs that are already proven. Early-stage rare disease biotechs are starving for capital, and the gap between winners and losers has never been wider.
The NIH killed funding for 383 clinical trials and $1.81 billion in grants in 2025, leaving 74,000 patients in limbo. Now the entire playbook for how trials get designed, funded, and run is being rewritten, and execution quality is the new currency investors care about most.
Cyprium Therapeutics just sold a Priority Review Voucher for $205 million, without ever selling a single dose of the drug that earned it. It's the most fascinating business model in biotech, and the voucher market is only getting hotter.
MoonLake's stock crashed 90% after a catastrophic Phase 3 miss in 2025. Five months later, the company just posted an 81% response rate in spinal arthritis, with PET scans showing it might actually slow irreversible bone damage.
The FDA just fast-tracked a gene therapy that could replace the grueling, round-the-clock cornstarch regimen keeping GSDIa patients alive. Ultragenyx's DTX401 showed a 60% reduction in cornstarch intake at 96 weeks, and the company built its own factory to make sure supply doesn't become the bottleneck.
Vanda Pharmaceuticals got Bysanti approved for bipolar I and schizophrenia without running a single Phase 3 trial, and its stock surged 40%. After seven years of jet lag rejection heartbreak, this clever regulatory strategy tells a bigger story about how drugs really get approved.
The FDA just handed BioMarin's achondroplasia monopoly three extra months of breathing room. Ascendis Pharma's once-weekly rival got delayed by a procedural amendment, and in rare disease, timing is everything.
Join thousands of biotech professionals who start their day with our free, daily briefing.